Published in ACS Chem Neurosci on May 25, 2010
Impaired striatal Akt signaling disrupts dopamine homeostasis and increases feeding. PLoS One (2011) 1.01
SLC6A3 coding variant Ala559Val found in two autism probands alters dopamine transporter function and trafficking. Transl Psychiatry (2014) 1.00
Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape. Expert Opin Ther Pat (2011) 0.87
mTORC2/rictor signaling disrupts dopamine-dependent behaviors via defects in striatal dopamine neurotransmission. J Neurosci (2015) 0.81
Kinase-dependent Regulation of Monoamine Neurotransmitter Transporters. Pharmacol Rev (2016) 0.78
Neuronal ablation of p-Akt at Ser473 leads to altered 5-HT1A/2A receptor function. Neurochem Int (2013) 0.78
Insulin Regulates the Activity of the High-Affinity Choline Transporter CHT. PLoS One (2015) 0.76
Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science (2001) 11.22
Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature (1996) 7.26
Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem (2001) 7.10
Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet (2004) 4.71
Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett (2005) 3.50
Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci U S A (2001) 3.23
Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci U S A (1998) 3.12
Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis. Development (2005) 3.02
Isoform-specific regulation of insulin-dependent glucose uptake by Akt/protein kinase B. J Biol Chem (2003) 2.76
The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle (2009) 2.62
Drug-activation of brain reward pathways. Drug Alcohol Depend (1998) 2.53
Molecular characterization of the dopamine transporter. Trends Pharmacol Sci (1993) 2.28
Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci U S A (2000) 2.27
Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol Cancer Ther (2005) 2.23
Life with a single isoform of Akt: mice lacking Akt2 and Akt3 are viable but display impaired glucose homeostasis and growth deficiencies. Mol Cell Biol (2006) 2.03
Physiological functions of protein kinase B/Akt. Biochem Soc Trans (2004) 2.00
Insulin receptors and insulin action in the brain: review and clinical implications. Neurosci Biobehav Rev (2000) 1.85
Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol Pharmacol (1992) 1.76
PI 3-kinase regulation of dopamine uptake. J Neurochem (2002) 1.64
Hypoinsulinemia regulates amphetamine-induced reverse transport of dopamine. PLoS Biol (2007) 1.48
Akt is essential for insulin modulation of amphetamine-induced human dopamine transporter cell-surface redistribution. Mol Pharmacol (2005) 1.47
The dopamine transporter proteome. J Neurochem (2006) 1.47
A regulated interaction of syntaxin 1A with the antidepressant-sensitive norepinephrine transporter establishes catecholamine clearance capacity. J Neurosci (2003) 1.35
Deficits in dopamine clearance and locomotion in hypoinsulinemic rats unmask novel modulation of dopamine transporters by amphetamine. J Neurochem (2005) 1.34
Further evidence for association of variants in the AKT1 gene with schizophrenia in a sample of European sib-pair families. Biol Psychiatry (2005) 1.26
Food deprivation decreases mRNA and activity of the rat dopamine transporter. Neuroendocrinology (1998) 1.24
Cloning and functional characterization of a cocaine-sensitive dopamine transporter. FEBS Lett (1991) 1.23
Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia. Neuropsychopharmacology (1994) 1.23
Selective, physiological transport of insulin across the blood-brain barrier: novel demonstration by species-specific radioimmunoassays. Peptides (1997) 1.22
GLUT4 translocation precedes the stimulation of glucose uptake by insulin in muscle cells: potential activation of GLUT4 via p38 mitogen-activated protein kinase. Biochem J (2001) 1.21
Biogenic amine neurotransmitter transporters: just when you thought you knew them. Physiology (Bethesda) (2005) 1.20
In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter. Biol Psychiatry (2005) 1.14
Group II and III metabotropic glutamate receptors suppress excitatory synaptic transmission in the dorsolateral bed nucleus of the stria terminalis. Neuropsychopharmacology (2005) 1.09
Amphetamine induces a calcium/calmodulin-dependent protein kinase II-dependent reduction in norepinephrine transporter surface expression linked to changes in syntaxin 1A/transporter complexes. Mol Pharmacol (2006) 1.06
Association of AKT1 haplotype with the risk of schizophrenia in Iranian population. Am J Med Genet B Neuropsychiatr Genet (2006) 1.03
The dopamine transporter: a vigilant border control for psychostimulant action. Handb Exp Pharmacol (2006) 1.02
Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity. Bioorg Med Chem Lett (2007) 0.98
PI3K signaling supports amphetamine-induced dopamine efflux. Biochem Biophys Res Commun (2008) 0.97
Uptake inhibitors but not substrates induce protease resistance in extracellular loop two of the dopamine transporter. Mol Pharmacol (2004) 0.93
Neurotransmitter transporters: why dance with so many partners? Curr Opin Pharmacol (2004) 0.90
Evidence that Akt mediates platelet-derived growth factor-dependent increases in activity and surface expression of the neuronal glutamate transporter, EAAC1. Neuropharmacology (2005) 0.86
Neurotransmitter transporters: new insights into structure, function and pharmacology. Rev Bras Biol (1996) 0.78
Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science (2006) 9.31
Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell (2007) 8.99
Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther (2006) 7.03
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov (2009) 6.69
Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science (2010) 5.86
Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol (2005) 5.13
Chromatin remodeling is a key mechanism underlying cocaine-induced plasticity in striatum. Neuron (2005) 5.09
Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli. Neuron (2007) 4.96
The mechanism of a neurotransmitter:sodium symporter--inward release of Na+ and substrate is triggered by substrate in a second binding site. Mol Cell (2008) 4.29
The top prescription drugs of 2009 in the US: CNS therapeutics rank among highest grossing. ACS Chem Neurosci (2010) 4.20
Essential role of the histone methyltransferase G9a in cocaine-induced plasticity. Science (2010) 3.97
Mania-like behavior induced by disruption of CLOCK. Proc Natl Acad Sci U S A (2007) 3.92
The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene (2005) 3.42
A comprehensive structure-based alignment of prokaryotic and eukaryotic neurotransmitter/Na+ symporters (NSS) aids in the use of the LeuT structure to probe NSS structure and function. Mol Pharmacol (2006) 3.23
Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci (2008) 3.22
Antidepressant actions of histone deacetylase inhibitors. J Neurosci (2009) 3.17
Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons. Nature (2012) 3.15
Cocaine regulates MEF2 to control synaptic and behavioral plasticity. Neuron (2008) 3.01
Dopamine D2 receptors form higher order oligomers at physiological expression levels. EMBO J (2008) 2.99
Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. Nat Chem Biol (2009) 2.98
Genome-wide analysis of chromatin regulation by cocaine reveals a role for sirtuins. Neuron (2009) 2.97
Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J Biol Chem (2002) 2.87
Cyanine fluorophore derivatives with enhanced photostability. Nat Methods (2011) 2.85
A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J Pharmacol Exp Ther (2004) 2.83
The fourth transmembrane segment forms the interface of the dopamine D2 receptor homodimer. J Biol Chem (2002) 2.75
The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat Neurosci (2008) 2.72
Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol (2009) 2.72
Application of combinatorial chemistry science on modern drug discovery. J Comb Chem (2008) 2.64
International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol Rev (2007) 2.62
A standardized protocol for repeated social defeat stress in mice. Nat Protoc (2011) 2.57
Single-molecule dynamics of gating in a neurotransmitter transporter homologue. Nature (2010) 2.41
Building a new conceptual framework for receptor heteromers. Nat Chem Biol (2009) 2.41
Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci (2009) 2.38
Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J Neurosci (2008) 2.34
Crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation. Proc Natl Acad Sci U S A (2005) 2.33
Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J Pharmacol Exp Ther (2008) 2.29
In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors. ACS Chem Biol (2010) 2.29
D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism. Mol Pharmacol (2007) 2.28
Monitoring the function of membrane transport proteins in detergent-solubilized form. Proc Natl Acad Sci U S A (2007) 2.27
A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol Pharmacol (2003) 2.27
The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. Annu Rev Pharmacol Toxicol (2002) 2.27
Mechanism of chloride interaction with neurotransmitter:sodium symporters. Nature (2007) 2.25
Binding of an octylglucoside detergent molecule in the second substrate (S2) site of LeuT establishes an inhibitor-bound conformation. Proc Natl Acad Sci U S A (2009) 2.25
Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol Cancer Ther (2005) 2.23
Ion/substrate-dependent conformational dynamics of a bacterial homolog of neurotransmitter:sodium symporters. Nat Struct Mol Biol (2010) 2.20
Substrate-modulated gating dynamics in a Na+-coupled neurotransmitter transporter homologue. Nature (2011) 2.18
Nuclear factor-kappaB is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proc Natl Acad Sci U S A (2010) 2.17
A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. J Pharmacol Exp Ther (2004) 2.17
Challenges in the development of mGluR5 positive allosteric modulators: the discovery of CPPHA. Bioorg Med Chem Lett (2006) 2.17
The top prescription drugs of 2010 in the United States: antipsychotics show strong growth. ACS Chem Neurosci (2011) 2.16
IκB kinase regulates social defeat stress-induced synaptic and behavioral plasticity. J Neurosci (2011) 2.15
The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice. Proc Natl Acad Sci U S A (2004) 2.10
Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. J Med Chem (2012) 2.10
Paternal transmission of stress-induced pathologies. Biol Psychiatry (2011) 2.07
An intracellular interaction network regulates conformational transitions in the dopamine transporter. J Biol Chem (2008) 2.07
Tyr-95 and Ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants. J Biol Chem (2005) 2.03
State-dependent conformations of the translocation pathway in the tyrosine transporter Tyt1, a novel neurotransmitter:sodium symporter from Fusobacterium nucleatum. J Biol Chem (2006) 2.01
Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate amphetamine-induced reverse transport. Neuron (2006) 2.00
Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc Natl Acad Sci U S A (2005) 1.98
Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A (2011) 1.98
DeltaFosB accumulates in a GABAergic cell population in the posterior tail of the ventral tegmental area after psychostimulant treatment. Eur J Neurosci (2005) 1.95
N-terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux. PLoS Biol (2004) 1.94
Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol Pharmacol (2008) 1.94
Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol Pharmacol (2010) 1.93
A surfactant protein C precursor protein BRICHOS domain mutation causes endoplasmic reticulum stress, proteasome dysfunction, and caspase 3 activation. Am J Respir Cell Mol Biol (2005) 1.90
"Molecular switches" on mGluR allosteric ligands that modulate modes of pharmacology. Biochemistry (2011) 1.89
Molecular determinants of selectivity and efficacy at the dopamine D3 receptor. J Med Chem (2012) 1.87
Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. Proc Natl Acad Sci U S A (2009) 1.87
Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res (2009) 1.84
mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning. Neuropsychopharmacology (2009) 1.80
Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold. Bioorg Med Chem Lett (2008) 1.78
Palmitic acid mediates hypothalamic insulin resistance by altering PKC-theta subcellular localization in rodents. J Clin Invest (2009) 1.77
A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learning. Mol Pharmacol (2009) 1.76
Orexin signaling mediates the antidepressant-like effect of calorie restriction. J Neurosci (2008) 1.76
Inhibition of the TRPC5 ion channel protects the kidney filter. J Clin Invest (2013) 1.76
G-protein-coupled receptors: from classical modes of modulation to allosteric mechanisms. ACS Chem Biol (2008) 1.76
DeltaFosB induction in orbitofrontal cortex mediates tolerance to cocaine-induced cognitive dysfunction. J Neurosci (2007) 1.74
The top prescription drugs of 2011 in the United States: antipsychotics and antidepressants once again lead CNS therapeutics. ACS Chem Neurosci (2012) 1.72
Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am J Psychiatry (2009) 1.71
Characterization of a functional bacterial homologue of sodium-dependent neurotransmitter transporters. J Biol Chem (2003) 1.70
Epigenetic regulation of RAC1 induces synaptic remodeling in stress disorders and depression. Nat Med (2013) 1.70
Amphetamine-induced dopamine efflux. A voltage-sensitive and intracellular Na+-dependent mechanism. J Biol Chem (2003) 1.69
Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol Pharmacol (2008) 1.68
Phospholipase D: enzymology, functionality, and chemical modulation. Chem Rev (2011) 1.66
PI 3-kinase regulation of dopamine uptake. J Neurochem (2002) 1.64
Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. J Neurosci (2003) 1.63
AKT signaling within the ventral tegmental area regulates cellular and behavioral responses to stressful stimuli. Biol Psychiatry (2008) 1.60
Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs). J Med Chem (2009) 1.59
Misfolded BRICHOS SP-C mutant proteins induce apoptosis via caspase-4- and cytochrome c-related mechanisms. Am J Physiol Lung Cell Mol Physiol (2007) 1.58
Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatins. J Med Chem (2009) 1.57
A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J Neurosci (2009) 1.57